You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

116 Results
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
ODB - General Benefit
    procarbazine
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
riTUXimab (Unfunded),
methotrexate,
procarbazine,
cytarabine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2020
Regimen
Cancer Type:
Endocrine, 
Thyroid
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
gemcitabine,
oxaliplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2020
Drug
Other Name(s): Zejula
Quick Link(s):
Drug Monograph, Patient Info Sheet
Mar 2025
Guidelines and Advice
Status: Current
Mar 2025
Guidelines and Advice
Status: Current
Mar 2025
Guidelines and Advice
Status: Current
ID: Guideline Endorsement C50-CIDAP-3
Mar 2025
Guidelines and Advice
Status: Current
ID: PET 2024-1
Mar 2025
Guidelines and Advice
Status: Current
ID: 5-9
Version: 2
Jan 2020

Pages